drugset

drugset / Trial / NCT06335979

An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

NCT06335979 ↗

Phase 1 Active not recruiting 54 enrolled Novartis Pharmaceuticals

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of PIT565 in participants with SLE

Timeline

Start: 2024-10-08
Primary completion: 2027-11-17
Completion: 2027-11-17

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PIT565	Unknown	—	Subcutaneous

Indications